Inventor · disambiguated record
Michael Wagner
Also filed as: WAGNER MICHAEL · WAGNER MICHAEL JAY
38 granted patents·12 pending applications·145 citations·filing 2003–2024
96Inventor score
Files withSANOFI SA32SANOFI AVENTIS DEUTSCHLAND5SANOFI AVENTIS3ANTAROS MEDICAL AB2KALLUS CHRISTOPHER2
Top patents by PatentIndex Score
50 records- 0191US9181305B2Exendin-4 peptide analoguesSANOFI SA·Filed 2013·Granted Nov 10, 2015·19 cites·44 claims
- 0290US9745360B2Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonistsSANOFI SA·Filed 2013·Granted Aug 29, 2017·14 cites·36 claims
- 0390US7465806B2Pyrrole-derivatives as factor Xa inhibitorsSANOFI AVENTIS DEUTSCHLAND·Filed 2006·Granted Dec 16, 2008·18 cites·9 claims
- 0488US9750788B2Non-acylated exendin-4 peptide analoguesSANOFI SA·Filed 2014·Granted Sep 5, 2017·11 cites·23 claims
- 0587US9365632B2Exendin-4 derivatives as dual GLP1/glucagon agonistsSANOFI SA·Filed 2013·Granted Jun 14, 2016·9 cites·38 claims
- 0686US7223780B2Triazole-derivatives as blood clotting enzyme factor Xa inhibitorsSANOFI AVENTIS DEUTSCHLAND·Filed 2004·Granted May 29, 2007·21 cites·9 claims
- 0784US12458606B2Polymer nanoparticle compositions for in vivo expression of polypeptidesBATTELLE MEMORIAL INSTITUTE·Filed 2024·Granted Nov 4, 2025·0 cites·8 claims
- 0884US9758561B2Dual GLP-1/glucagon receptor agonists derived from exendin-4SANOFI SA·Filed 2015·Granted Sep 12, 2017·6 cites·34 claims
- 0982US9309207B2Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIaSANOFI SA·Filed 2015·Granted Apr 12, 2016·3 cites·17 claims
- 1081US9775904B2Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonistsSANOFI SA·Filed 2015·Granted Oct 3, 2017·4 cites·27 claims
- 1181US9771406B2Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4SANOFI SA·Filed 2015·Granted Sep 26, 2017·4 cites·31 claims
- 1280US9789165B2Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonistsSANOFI SA·Filed 2014·Granted Oct 17, 2017·4 cites·23 claims
- 1380US9751926B2Dual GLP-1/GIP receptor agonistsSANOFI SA·Filed 2014·Granted Sep 5, 2017·4 cites·27 claims
- 1480US8580777B2Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIaKALLUS CHRISTOPHER·Filed 2009·Granted Nov 12, 2013·4 cites·17 claims
- 1579US9694053B2Dual GLP-1/glucagon receptor agonistsSANOFI SA·Filed 2014·Granted Jul 4, 2017·4 cites·22 claims
- 1679US9126955B2Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIaSANOFI SA·Filed 2014·Granted Sep 8, 2015·3 cites·15 claims
- 1777US10538567B2Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonistsSANOFI SA·Filed 2017·Granted Jan 21, 2020·2 cites·38 claims
- 1877US10519211B2Compounds as peptidic GLP1/glucagon/GIP receptor agonistsSANOFI SA·Filed 2017·Granted Dec 31, 2019·2 cites·30 claims
- 1977US8722655B2Macrocyclic urea and sulfamide derivatives as inhibitors of tafiaKALLUS CHRISTOPHER·Filed 2013·Granted May 13, 2014·3 cites·18 claims
- 2076US9982029B2Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonistsSANOFI SA·Filed 2016·Granted May 29, 2018·2 cites·34 claims
- 2176US9670261B2Functionalized exendin-4 derivativesSANOFI SA·Filed 2013·Granted Jun 6, 2017·2 cites·49 claims
- 2276US8039480B2Spirocyclic nitriles as protease inhibitorsSANOFI AVENTIS·Filed 2008·Granted Oct 18, 2011·2 cites·23 claims
- 2376US2010114601A1System and methods for prescribing therapeutic and preventive regimensCERNER INNOVATION INC·Filed 2009·Application pending·0 cites
- 2474US10792367B2Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acidSANOFI SA·Filed 2017·Granted Oct 6, 2020·1 cites·36 claims
- 2563US11046743B2Selective glucagon receptor agonists comprising a chelating moiety for imaging purposesANTAROS MEDICAL AB·Filed 2016·Granted Jun 29, 2021·1 cites·20 claims
- 2662US7358268B2Imidazole derivatives as factor Xa inhibitorsSANOFI AVENTIS DEUTSCHLAND·Filed 2003·Granted Apr 15, 2008·2 cites·5 claims
- 2759US2025164485A1Site-specific conjugation of single domain antibody fragments (vhh) using equilibrium transfer alkylation reagent (etac)MILTENYI BIOTEC BV & CO KG·Filed 2024·Application pending·0 cites
- 2859US2024360194A1New Peptides as Potent and Selective GIP Receptor AgonistsSANOFI SA·Filed 2022·Application pending·0 cites
- 2956US9688645B2Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIaSANOFI SA·Filed 2016·Granted Jun 27, 2017·0 cites·17 claims
- 3055US10758592B2Exendin-4 derivatives as dual GLP1/glucagon agonistsSANOFI SA·Filed 2017·Granted Sep 1, 2020·0 cites·23 claims
- 3155US2014073662A1Spirocyclic nitriles as protease inhibitorsSANOFI SA·Filed 2013·Application pending·0 cites
- 3254US10253079B2Functionalized Exendin-4 derivativesSANOFI SA·Filed 2017·Granted Apr 9, 2019·0 cites·30 claims
- 3352US11141489B2Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acidSANOFI SA·Filed 2019·Granted Oct 12, 2021·0 cites·20 claims
- 3451US2023103631A1Peptides as selective gip receptor agonistsSANOFI SA·Filed 2021·Application pending·0 cites
- 3551US2023295227A1Compounds for use in diagnosis and/or monitoring of fibrosisANTAROS TRACER AB·Filed 2021·Application pending·0 cites
- 3650US2016220643A1Exendin-4 derivatives as dual glp1/glucagon agonistsSANOFI SA·Filed 2016·Application pending·0 cites
- 3750US2023127047A1Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposesANTAROS MEDICAL AB·Filed 2021·Application pending·0 cites
- 3849US7825264B2Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising themSANOFI AVENTIS·Filed 2007·Granted Nov 2, 2010·0 cites·7 claims
- 3948US8088925B2Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitorsWAGNER MICHAEL·Filed 2007·Granted Jan 3, 2012·0 cites·3 claims
- 4048US8044074B2Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising themSANOFI AVENTIS·Filed 2007·Granted Oct 25, 2011·0 cites·6 claims
- 4148US2020023070A1Conjugates comprising an glp-1/glucagon/gip triple receptor agonist, a linker and hyaluronic acidSANOFI SA·Filed 2019·Application pending·0 cites
- 4246US2015166625A1Exendin-4 Peptide AnaloguesSANOFI SA·Filed 2014·Application pending·0 cites
- 4346US2017022260A9Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonistsSANOFI SA·Filed 2014·Application pending·0 cites
- 4445US9834527B2Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticalsSANOFI SA·Filed 2014·Granted Dec 5, 2017·0 cites·9 claims
- 4545US8609681B2Spirocyclic nitriles as protease inhibitorsSCHUDOK MANFRED·Filed 2011·Granted Dec 17, 2013·0 cites·15 claims
- 4645US2007179122A1Beta-Aminoacid-Derivatives As Factor Xa InhibitorsSANOFI AVENTIS DEUTSCHLAND·Filed 2006·Application pending·0 cites
- 4744US7741341B2Benzimidazole-derivatives as factor Xa inhibitorsSANOFI AVENTIS DEUTSCHLAND·Filed 2004·Granted Jun 22, 2010·0 cites·19 claims
- 4841US10806797B2Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugateSANOFI SA·Filed 2016·Granted Oct 20, 2020·0 cites·28 claims
- 4939US11352405B2GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitisSANOFI SA·Filed 2018·Granted Jun 7, 2022·0 cites·17 claims
- 5037US9932381B2Exendin-4 derivatives as selective glucagon receptor agonistsSANOFI SA·Filed 2015·Granted Apr 3, 2018·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when Michael Wagner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →